Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 20 of 20 entries
View as:

Single Ascending Dose Safety, Tolerability and Pharmacokinetics Study of GLYX-13 in Normal Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01014650 Org: User:
Start: 11/30/09 End: 10/31/15 Due: 10/31/16

Study of Intravenous NRX-1074 in Patients With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT02067793 Org: User:
Start: 03/31/14 End: 02/28/15 Due: 02/28/16

A Study of Rapastinel for Rapid Treatment of Depression and Suicidality in Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03352453 Org: User:
Start: 12/15/17 End: 06/21/19 Due: 06/21/20

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-02)

Phase: N/A Priority: Normal
NCT ID: NCT02943564 Org: User:
Start: 11/01/16 End: 12/18/18 Due: 12/18/19

Assessment of Abuse Potential of Rapastinel in Humans

Phase: N/A Priority: Normal
NCT ID: NCT03799900 Org: User:
Start: 11/01/18 End: 03/29/19 Due: 03/29/20

A Study of Rapastinel as Adjunctive Therapy in the Prevention of Relapse in Patients With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT02951988 Org: User:
Start: 11/13/16 End: 02/22/19 Due: 02/22/20

Study of Rapastinel as Monotherapy in Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT03855865 Org: User:
Start: 07/01/19 End: 12/31/20 Due: 12/31/21

Assessment of Effect of Rapastinel on Driving Performance

Phase: N/A Priority: Normal
NCT ID: NCT03814733 Org: User:
Start: 11/05/18 End: 04/03/19 Due: 04/03/20

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-03)

Phase: N/A Priority: Normal
NCT ID: NCT02943577 Org: User:
Start: 11/02/16 End: 11/21/18 Due: 11/21/19

Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression

Phase: N/A Priority: Normal
NCT ID: NCT01234558 Org: User:
Start: 05/31/11 End: 07/31/12 Due: 07/31/13

Safety and Pharmacokinetics of NRX-1074 in Normal Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT01856556 Org: User:
Start: 05/31/13 End: 11/30/14 Due: 11/30/15

Study of Rapastinel as Monotherapy in Patients With MDD

Phase: N/A Priority: Normal
NCT ID: NCT03560518 Org: User:
Start: 06/15/18 End: 07/08/19 Due: 07/08/20

Open Label Extension for GLYX13-C-202, NCT01684163

Phase: N/A Priority: Normal
NCT ID: NCT02192099 Org: User:
Start: 09/08/14 End: 11/08/18 Due: 11/08/19

Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients With Major Depressive Disorder

Phase: N/A Priority: Normal
NCT ID: NCT03002077 Org: User:
Start: 02/03/17 End: 12/06/18 Due: 12/06/19

Study of Monotherapy Rapastinel in the Prevention of Relapse in Patients With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT03614156 Org: User:
Start: 08/02/18 End: 07/11/19 Due: 07/11/20

A Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder (RAP-MD-01)

Phase: N/A Priority: Normal
NCT ID: NCT02932943 Org: User:
Start: 10/15/16 End: 11/08/18 Due: 11/08/19

Study of Safety, Tolerability and Pharmacokinetics of NRX-1074 in Normal Healthy Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02366364 Org: User:
Start: 02/28/15 End: 04/30/15 Due: 04/30/16

Study of Adjunctive or Monotherapy Rapastinel Treatment in Patients With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT03668600 Org: User:
Start: 08/23/18 End: 07/03/19 Due: 07/03/20

Efficacy and Safety of GLYX-13 in Subjects With Inadequate/Partial Response to Antidepressants

Phase: N/A Priority: Normal
NCT ID: NCT01684163 Org: User:
Start: 11/30/12 End: 06/30/14 Due: 06/30/15

Study of Rapastinel as Monotherapy in Patients With Major Depressive Disorder (MDD)

Phase: N/A Priority: Normal
NCT ID: NCT03675776 Org: User:
Start: 10/30/18 End: 07/11/19 Due: 07/11/20